{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Oldroyd AGS"],"funding":["National Health Service","National Institute for Health Research Manchester Biomedical Research Centre","Versus Arthritis","National Institute for Health Research (NIHR)","National Institute for Health Research Manchester Biomedical Research Centre Funding Scheme","The Myositis Association"],"pagination":["4845-4854"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9707041"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["61(12)"],"pubmed_abstract":["<h4>Objective</h4>The objective of this study was to use daily data collected via a smartphone app for characterization of patient-reported and symptom-based (using an a priori definition) flares in an adult idiopathic inflammatory myopathy (IIM) cohort.<h4>Methods</h4>UK adults with an IIM answered patient-reported outcome measurements (PROMs) daily via a smartphone app during a 91-day study. Daily symptom PROMs addressed global activity, overall pain, myalgia, fatigue, and weakness (on a 0-100 visual analogue scale). Patient-reported flares were recorded via a weekly app question. Symptom-based flares were defined via an a priori definition related to increase in daily symptom data from the previous 4-day mean.<h4>Results</h4>Twenty participants (65% female) participated. Patient-reported flares occurred on a median of 5 weeks (IQR 3, 7) per participant, out of a possible 13. The mean of each symptom score was significantly higher in flare weeks, compared with non-flare weeks (e.g. mean flare week myalgia score 34/100, vs 21/100 during non-flare week, t test P-value <0.01). Fatigue accounted for the most symptom-based flares [incidence-rate 23/100 person-days (95% CI 19, 27)], and myalgia the fewest [incidence rate 13/100 person-days (95% CI 11, 16)]. Symptom-based flares typically resolved after 3 days, although fatigue-predominant flares lasted 2 days. The majority (69%) of patient-reported flare weeks coincided with at least one symptom-based flare.<h4>Conclusions</h4>IIM flares are frequent and associated with increased symptom scores. This study has demonstrated the ability to identify and characterize patient-reported and symptom-based flares (based on an a priori definition), using daily app-collected data."],"journal":["Rheumatology (Oxford, England)"],"pubmed_title":["Investigating characteristics of idiopathic inflammatory myopathy flares using daily symptom data collected via a smartphone app."],"pmcid":["PMC9707041"],"funding_grant_id":["21993","NIHR-INF-0545"],"pubmed_authors":["Oldroyd AGS","Chinoy H","Dixon WG","Krogh NS"],"additional_accession":[]},"is_claimable":false,"name":"Investigating characteristics of idiopathic inflammatory myopathy flares using daily symptom data collected via a smartphone app.","description":"<h4>Objective</h4>The objective of this study was to use daily data collected via a smartphone app for characterization of patient-reported and symptom-based (using an a priori definition) flares in an adult idiopathic inflammatory myopathy (IIM) cohort.<h4>Methods</h4>UK adults with an IIM answered patient-reported outcome measurements (PROMs) daily via a smartphone app during a 91-day study. Daily symptom PROMs addressed global activity, overall pain, myalgia, fatigue, and weakness (on a 0-100 visual analogue scale). Patient-reported flares were recorded via a weekly app question. Symptom-based flares were defined via an a priori definition related to increase in daily symptom data from the previous 4-day mean.<h4>Results</h4>Twenty participants (65% female) participated. Patient-reported flares occurred on a median of 5 weeks (IQR 3, 7) per participant, out of a possible 13. The mean of each symptom score was significantly higher in flare weeks, compared with non-flare weeks (e.g. mean flare week myalgia score 34/100, vs 21/100 during non-flare week, t test P-value <0.01). Fatigue accounted for the most symptom-based flares [incidence-rate 23/100 person-days (95% CI 19, 27)], and myalgia the fewest [incidence rate 13/100 person-days (95% CI 11, 16)]. Symptom-based flares typically resolved after 3 days, although fatigue-predominant flares lasted 2 days. The majority (69%) of patient-reported flare weeks coincided with at least one symptom-based flare.<h4>Conclusions</h4>IIM flares are frequent and associated with increased symptom scores. This study has demonstrated the ability to identify and characterize patient-reported and symptom-based flares (based on an a priori definition), using daily app-collected data.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2025-04-26T09:51:40.276Z","creation":"2025-04-06T13:07:48.903Z"},"accession":"S-EPMC9707041","cross_references":{"pubmed":["35274670"],"doi":["10.1093/rheumatology/keac161"]}}